ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment

Hepatitis Clinical Trial

— ECPforIRAE  

Official title:

Multicenter Retrospective Cohort Study on Patients Receiving Extracorporeal Photopheresis for Immune-related Adverse Events After Checkpoint Inhibitor Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05414552
• Other study ID #: UKLFR06062022
• Status: Completed
• Start date: June 1, 2021
• Est. completion date: December 30, 2022

Study information

• Verified date: July 2023
• Source: University of Freiburg
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Preliminary data demonstrate that irAEs induced by immune checkpoint blockade can be successfully treated with ECP (Apostolova et al. NEJM 2020). Therefore this retrospective analysis is launched to validate the finding made with the individual patient in a larger patient cohort. The analysis will include the evaluation of safety of ECP treatment in patients with irAEs and collect data on the efficacy of ECP as a treatment for immune-related adverse events and its effect on tumor progression.

Description:

Immune checkpoint inhibitors (ICI) have improved the long-term survival of patients with metastatic tumors. However, approximately 50% of the patients treated with ICI develop serious immune-related adverse events (irAE). A recent study reported that grade 3 or higher irAE occurred in 49 of 124 patients (39.5%) who received nivolumab/ipilimumab and in 41 of 123 patients (33.3%) who received nivolumab alone. Other studies report an overall frequency of grade 3-5 irAE in 24% - 59% of patients treated with nivolumab 1 mg/kg body weight and ipilimumab 3 mg/kg body weight. An incidence of 33.3% was reported when patients were treated with nivolumab 3 mg/kg body weight and ipilimumab 1 mg/kg body weight. The most common events reported during combined ICI treatment are diarrhea, rash, pruritus, hepatitis, hypothyroidism, neurological disease and pneumonitis. These numbers show that irAE are a particularly frequent complication of ICI and limit their use. This retrospective analysis is launched to validate the finding made with the individual patient in a larger patient cohort. The analysis will include the evaluation of safety of ECP treatment in patients with irAEs and collect data on the efficacy of ECP as a treatment for immune-related adverse events and its effect on tumor progression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: December 30, 2022
• Est. primary completion date: December 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male and female patients aged =18 years

2. Written informed consent:

• Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines.
• Subjects must be able to understand and willing to comply with scheduled visits, treatment schedule, laboratory tests and mandatory collection of blood, and other requirements of the study.
• Subject Re-enrollment: This trial permits the re-enrollment of a subject that has discontinued the study as a screening failure. If re-enrolled, the subject must be re-consented.

3. Target population

• Patients who have received treatment with an anti-PD-1, anti-PD-L1 or an anti-CTLA-4 antibody or any combination of these for any type of malignancy in the last 24 months before screening.
• Patients should have clinical and/or histological evidence of immune-related

adverse events as follows:

• Colitis Diarrhea with increase of =4 stools over baseline No improvement after 72h treatment with at least 1 mg/kg BW/day prednisolone equivalent
• Hepatitis Alanine aminotransferase and/or aspartate aminotransferase =3x ULN if baseline was normal; or =3x baseline if baseline was abnormal No improvement after 72h treatment with at least 1 mg/kg BW/day prednisolone equivalent
• Pneumonitis Radiographic changes and new symptoms such as cough, dyspnea or chest pain No improvement after 72h treatment with 1 mg/kg BW/day prednisolone equivalent Dermatitis Skin erythema, maculopapular or pustulopapular rash covering =30% of the body surface area No improvement after 72h treatment with at least 1 mg/kg BW/day prednisolone equivalent

4. Maximum of one additional (second line) therapy after Steroid treatment before ECP starts (e.g. infliximab for colitis)

5. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 1 week prior to the start of study drug.

6. Women must not be breastfeeding.

7. ECOG performance status 0, 1, or 2

Exclusion Criteria:

1. Active treatment in a clinical study of any investigational agent within 14 days prior day 0 or within 5 half-lives of the study treatment, whichever is greater.

2. Positive result for HIV.

3. Prior allogeneic bone marrow transplantation or prior solid organ transplantation.

4. Mechanical ventilation or patients who have resting O2 saturation <90% by pulse-oximetry.

5. Patients who require vasopressors, and/or have NYHA class III or IV heart failure.

6. Uncontrolled hypertension or ventricular arrhythmias.

7. Previous or concurrent malignancies within the last 3 years of enrollment other than the disease for which checkpoint-inhibitor blockade was applied. Exceptions are adequately treated basal or squamous cell skin cancer, or any other cancer from which the subject has been disease-free for more than 3 years.

8. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data

9. Known allergies, hypersensitivity, or intolerance of methoxypsoralen, excipients, or similar compounds, heparin or similar compounds

10. Aphakia

11. Female patients of child-bearing potential who are not willing to use highly effective methods of contraception during the trial and at least 5 months after the ECP procedure (see also 10.9)

12. Inability to tolerate extracorporeal volume loss

13. Previous splenectomy

14. Pregnancy and lactation

Related Conditions & MeSH terms

• Colitis
• Dermatitis
• Hepatitis
• Immune Related Adverse Events

Intervention

Drug:
• ECP
Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks

Locations

Country	Name	City	State
Germany	Medical Center - University of Freiburg Albert-Ludwigs-University Freiburg Department of Medicine I	Freiburg	Baden-Württemberg

Sponsors (1)

Lead Sponsor	Collaborator
University of Freiburg

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Apostolova P, Unger S, von Bubnoff D, Meiss F, Becher B, Zeiser R. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy. N Engl J Med. 2020 Jan 16;382(3):294-296. doi: 10.1056/NEJMc1912274. No abstract available. — View Citation

Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft- — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety - treatment-related adverse events (AEs) and severe adverse events (SAEs)	To evaluate the rate of treatment-related adverse events (AEs) and severe adverse events (SAEs) in patients treated with ECP for immune-checkpoint inhibitor-induced colitis, pneumonitis, hepatitis or dermatitis.	12 months after end of ECP
Secondary	objective response rate	objective response rate (ORR) to treatment after 6 weeks of ECP therapy	After 6 weeks of ECP therapy